EPISODE · May 13, 2026 · 1 MIN
Avidity Partners Invests $9M in Aktis Oncology
from The Daily News Now! Business
Avidity Partners Management invests $9.1M in Aktis Oncology, marking a new bet for the biotech fund. Aktis develops targeted radiopharmaceuticals for cancer treatment, with lead drugs AKY-1189 and AKY-2519. The investment, valued at $8.79M, represents approximately 2% of Aviditys reportable assets. Aktiss market cap reached $1B, with TTM revenue of $6.5M and a net loss of $63.73M. This move by Avidity signals confidence in Aktiss pipeline, making it an oncology investment to watch. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cca89b8188e476fe
NOW PLAYING
Avidity Partners Invests $9M in Aktis Oncology
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m